The emerging landscape of tyrosine kinase inhibitors have shown to significantly enhance the survival rates in cancer patients owing to their ability to specifically target the genomic alterations which are critical for the progression of cancer.
Global PDGFR Inhibitors Market, Drug Sales and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 (Qinlock and Ayvakit)
- Approved PGDFR Drug Patent, Price and Sales insight 2020 Till 2026
- Future market Assessment By Indication and Region Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
The emerging landscape of tyrosine kinase inhibitors have shown to significantly enhance the survival rates in cancer patients owing to their ability to specifically target the genomic alterations which are critical for the progression of cancer. The identification of platelet derived growth factor receptor (PDGFR) as a potential therapeutic target has led to arrival of several PDGFR inhibitors for the management of cancer. The combination of its high specificity along with few associated side effects has pushed the overall paradigm of cancer treatment towards more targeted nature of therapy.
The withdrawal of first PDGFR inhibitor, Larturvo has subsequently led to approval of other PDGFR inhibitors which have the ability to overcome the limitations of previously approved drug. The currently market PDGFR inhibitors including Qinlock and Ayvakit have demonstrated high efficacy in targeting resistant PDGFRA D842V mutations and have shown durable response across multiple lines of treatment. Moreover, as a broad spectrum kinase inhibitor, the drug also inhibits other various gene mutations and increased progression free survival in advanced gastrointestinal tumors.
By analyzing the large number of clinical trials, the report Global PDGFR inhibitor market suggests that the drugs will also gain extended approval in other therapeutic conditions including glioma, colorectal cancer, acute myeloid leukemia, lung cancer, and others. Furthermore, the future is expected to witness wide range of combinational therapies involving PDGFR inhibitors with chemotherapy, immunotherapy, and other small molecule tyrosine kinase inhibitors which aim to enhance the efficacy and targetability in target patients. The rapid approval of these drugs in combination as well as in other cancers will propel the growth of market during the forecasted period.
Apart from several favorable parameters, the overall market is expected to be restrained by the high cost of therapy, slow drug approvals and regulatory obligations. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years. In addition, technological advancements in field of science have also enabled to fasten the overall drug development process and reduce the associated cost. Apart from this, rising initiatives by government and other private sectors has enabled favorable reimbursement policies which reduce the financial toxicity on patient and increase the adoption rates of novel targeted drugs in the market.
The great zeal of interest in PDGFR inhibitors can be further justified by the large investment made by pharmaceutical companies in this sector. The pipeline of these drugs is highly crowded and majorly consists of Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001. These drugs are majorly present in phase-I/II clinical trials, suggesting that the market will see rapid influx of novel PDGFR inhibitors in forthcoming years. In addition, pharmaceutical giants have adopted several novel strategies including alliance, collaboration or partnerships which aid in securing their position worldwide. The PDGFR inhibitor market is highly competitive and consists of several players including Arog Pharmaceutical, Eli Lilly, Clovis Oncology, AstraZeneca, Bayer, and several others.
Keeping in mind the robust sales of approved drugs in US, the report predicts that the region will continue to maintain its dominant share in the global market. In addition, other factors including large target population base, presence of majority key players, favorable reimbursement policies, and increasing awareness about novel targeted cancer drugs will also propel their growth in the region. Furthermore, it is suggested that the drugs will also gain approval in Japan due to favorable policies framework for easy drug approval, production, and marketing by the Japanese government. The rest of world region is also anticipated to register high CAGR rates due to presence of several untapped opportunities and rising awareness among population.
Contact:
Neeraj Chawla
Research Head
neeraj@kuickresearch.com
+91-9810410366